Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Editorial introductions

Editorial introductions Current Opinion in HIV and AIDS was launched in 2006. It currently used in the treatment of various virus infections, is one of a successful series of review journals whose such as herpes simplex (valaciclovir), herpes zoster unique format is designed to provide a systematic and (brivudin), AIDS (stavudine), CMV (cytomegalovirus) critical assessment of the literature as presented in the infections (cidofovir), HBV (hepatitis B virus) infections many primary journals. The fields of HIV and AIDS are (adefovir), and HIV infections (AIDS) (tenofovir diso- divided into 6 sections that are reviewed once a year. proxil fumarate, marketed as Viread, and, in combination Each section is assigned a Section Editor, a leading with emtricitabine, as Truvada, and, in combination with authority in the area, who identifies the most important both emtricitabine and efavirenz, as Atripia). topics at that time. Here we are pleased to introduce the Journal’s Section Editors for this issue. Joel E. Gallant Joel E. Gallant, MD, MPH is Section Editors Professor of Medicine in the Division of Infectious Dis- Erik De Clercq eases at the Johns Hopkins Erik De Clercq was born in University School of Medi- Dendermonde, Belgium, on cine in Baltimore and Pro- March 28, 1941. He received fessor of Epidemiology at his MD degree in 1966 and the Johns Hopkins Bloom- his PhD in 1972 both at berg School of Public Health. the Katholieke Universiteit He is the Associate Director Leuven (K.U.Leuven) in of the Johns Hopkins AIDS Belgium. After having spent Service. He is Director of the two years at Stanford Uni- Garey Lambert Research versity Medical School as a Center, through which he has conducted dozens of clinical postdoctoral fellow, he trials on the treatment of HIV infection. He is also an returned to the K.U.Leuven investigator in the HIV Prevention Trials Network (HPTN), the Acute Infection Early Disease Research Medical School, where he Program (AIEDRP), the Multicenter AIDS Cohort became docent (assistant professor) in 1973, professor in (MACS), and the AIDS Clinical Trials Group (ACTG). 1975, and full professor in 1977. As of today he is teaching Within the HPTN and ACTG he has been involved the courses of Cell Biology, Biochemistry, Microbiology in international clinical trials, especially in Chiang Mai, and Virology in the first, second and third undergraduate Thailand. He is a member of the Governing Council of years of the Medical School at the K.U.Leuven and K.U.Leuven Campus Kortrijk. Professor E. De Clercq the International AIDS Society, and is on the Board served as chairman of the Department of Microbiology of Directors of the International AIDS Society-USA. from 1986 – 1991. Since 1999 he is again serving as chair- Dr Gallant received his MD at the University of California, man of the Department of Microbiology and Immunology. San Francisco. He completed a residency and chief resi- In 1985, he became President of the Rega Foundation and, dency in internal medicine at Yale-New Haven Hospital. in 1986, Chairman of the Directory Board of the Rega He received his MPH at the Johns Hopkins University Institute for Medical Research, two positions which he still School of Medicine. He is a fellow of the Infectious holds. He is a titular member of the Belgian Royal Acad- Diseases Society of America and the American College emy of Medicine and the Academia Europaea, and has also of Physicians. Dr Gallant is co-author, with John G. held the Professor P. De Somer Chair of Microbiology at Bartlett, of the Medical Management of HIV Infection, which the K.U.Leuven. Professor De Clercq’s scientific achieve- is updated annually. He is an associate editor of The ments are in the antiviral chemotherapy field, and, in Hopkins HIV Report and is on the Editorial Board of the particular, the development of new antiviral agents for Johns Hopkins AIDS Service Web site, where he conducts the treatment of various viral infections, including AIDS. interactive question and answer forums on HIV disease for He has (co)-discovered a number of antiviral drugs, patients and clinicians. Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Editorial introductions

Current Opinion in HIV and Aids , Volume 1 (5) – Sep 1, 2006
Download PDF
1 page

Loading next page...
 
/lp/wolters-kluwer-health/editorial-introductions-BNMVWLyffL

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/01.COH.0000239845.28452.17
Publisher site
See Article on Publisher Site

Abstract

Current Opinion in HIV and AIDS was launched in 2006. It currently used in the treatment of various virus infections, is one of a successful series of review journals whose such as herpes simplex (valaciclovir), herpes zoster unique format is designed to provide a systematic and (brivudin), AIDS (stavudine), CMV (cytomegalovirus) critical assessment of the literature as presented in the infections (cidofovir), HBV (hepatitis B virus) infections many primary journals. The fields of HIV and AIDS are (adefovir), and HIV infections (AIDS) (tenofovir diso- divided into 6 sections that are reviewed once a year. proxil fumarate, marketed as Viread, and, in combination Each section is assigned a Section Editor, a leading with emtricitabine, as Truvada, and, in combination with authority in the area, who identifies the most important both emtricitabine and efavirenz, as Atripia). topics at that time. Here we are pleased to introduce the Journal’s Section Editors for this issue. Joel E. Gallant Joel E. Gallant, MD, MPH is Section Editors Professor of Medicine in the Division of Infectious Dis- Erik De Clercq eases at the Johns Hopkins Erik De Clercq was born in University School of Medi- Dendermonde, Belgium, on cine in Baltimore and Pro- March 28, 1941. He received fessor of Epidemiology at his MD degree in 1966 and the Johns Hopkins Bloom- his PhD in 1972 both at berg School of Public Health. the Katholieke Universiteit He is the Associate Director Leuven (K.U.Leuven) in of the Johns Hopkins AIDS Belgium. After having spent Service. He is Director of the two years at Stanford Uni- Garey Lambert Research versity Medical School as a Center, through which he has conducted dozens of clinical postdoctoral fellow, he trials on the treatment of HIV infection. He is also an returned to the K.U.Leuven investigator in the HIV Prevention Trials Network (HPTN), the Acute Infection Early Disease Research Medical School, where he Program (AIEDRP), the Multicenter AIDS Cohort became docent (assistant professor) in 1973, professor in (MACS), and the AIDS Clinical Trials Group (ACTG). 1975, and full professor in 1977. As of today he is teaching Within the HPTN and ACTG he has been involved the courses of Cell Biology, Biochemistry, Microbiology in international clinical trials, especially in Chiang Mai, and Virology in the first, second and third undergraduate Thailand. He is a member of the Governing Council of years of the Medical School at the K.U.Leuven and K.U.Leuven Campus Kortrijk. Professor E. De Clercq the International AIDS Society, and is on the Board served as chairman of the Department of Microbiology of Directors of the International AIDS Society-USA. from 1986 – 1991. Since 1999 he is again serving as chair- Dr Gallant received his MD at the University of California, man of the Department of Microbiology and Immunology. San Francisco. He completed a residency and chief resi- In 1985, he became President of the Rega Foundation and, dency in internal medicine at Yale-New Haven Hospital. in 1986, Chairman of the Directory Board of the Rega He received his MPH at the Johns Hopkins University Institute for Medical Research, two positions which he still School of Medicine. He is a fellow of the Infectious holds. He is a titular member of the Belgian Royal Acad- Diseases Society of America and the American College emy of Medicine and the Academia Europaea, and has also of Physicians. Dr Gallant is co-author, with John G. held the Professor P. De Somer Chair of Microbiology at Bartlett, of the Medical Management of HIV Infection, which the K.U.Leuven. Professor De Clercq’s scientific achieve- is updated annually. He is an associate editor of The ments are in the antiviral chemotherapy field, and, in Hopkins HIV Report and is on the Editorial Board of the particular, the development of new antiviral agents for Johns Hopkins AIDS Service Web site, where he conducts the treatment of various viral infections, including AIDS. interactive question and answer forums on HIV disease for He has (co)-discovered a number of antiviral drugs, patients and clinicians. Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Sep 1, 2006

There are no references for this article.